Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results

Dr. Laura Huppert presents key data from the DESTINY-Breast12 study, showcasing the effects of trastuzumab deruxtecan on health-related quality of life and neurological function in HER2+ metastatic breast cancer patients, with findings demonstrating preserved quality of life and neurological stability, regardless of brain metastasis status.